Boots Brings Medical Cannabis Into UK Pharmacies

Boots, one of the UK's largest pharmacy chains, has launched a specialist medical cannabis service. The move could have interesting implications for South Africa, where private cannabis use and medical regulations remain separate legal issues.

Writer: Andrew Macfarlane

Medical cannabis is moving closer to mainstream healthcare in the UK.

Boots, the well-known British pharmacy chain, has launched SureLeaf, a new service offering medical cannabis consultations and prescriptions to eligible patients.

For many people in the UK, this marks a significant change in how cannabis-based treatments are being introduced to the public.

Instead of relying exclusively on specialist cannabis clinics, eligible patients can now access assessments through a familiar pharmacy brand.

However, this doesn’t mean you can simply walk into Boots and buy cannabis.

The service operates through Boots Online Doctor, with specialist medical supervision and strict eligibility requirements.

Some South Africans might not find this news surprising, considering how common cannabis outlets have become in many areas.

However, for patients struggling to obtain Section 21 approval for medical cannabis, the Boots model could offer some valuable lessons about improving access to regulated treatment.

Boots Launches Medical Cannabis Prescriptions in the UK

According to Boots’ official announcement, eligible patients may be considered for cannabis-based treatment when conventional therapies haven’t provided sufficient relief.

The service focuses on three main categories:

  • Chronic pain conditions, including neuropathic pain, fibromyalgia and arthritis.
  • Generalised anxiety disorder.
  • Insomnia disorder.


Patients must be at least 25 years old and meet the service’s clinical eligibility requirements.

The process starts with an online assessment. A clinical team then reviews the patient’s suitability before arranging a video consultation with a specialist doctor.

Any proposed prescription is independently reviewed by a multidisciplinary clinical team that includes a second specialist consultant.

Patients who begin treatment receive ongoing monitoring, including an initial review after 28 days and follow-up consultations at least every three months.

The service is privately funded and isn’t part of the National Health Service (NHS).

It’s important to remember that medical cannabis isn’t an established first-line treatment for these conditions. Research into its effectiveness, safety and appropriate clinical use is still ongoing.

Boots is also exploring a research collaboration with the University of Nottingham to study patient outcomes, particularly among people receiving treatment for chronic pain.

Why the Boots Announcement Is Such Big News

The UK legalised specialist prescriptions for certain cannabis-based medicines in November 2018.

However, having a legal treatment option doesn’t necessarily mean it’s easy to access.

For years, much of the UK’s medical cannabis treatment has been provided through private specialist clinics. Access through the NHS remains considerably more restricted.

Now, Boots is introducing medical cannabis through a pharmacy brand that millions of people already recognise.

With its established healthcare infrastructure and familiar name, Boots could help make medical cannabis a more common topic of conversation between patients and doctors.

That doesn’t mean medical cannabis will suddenly become affordable or widely accessible.

However, it does signal a shift in how cannabis is being viewed.

Rather than treating cannabis exclusively as a controversial substance, a major pharmacy chain is recognising certain cannabis-based medicines as potential treatment options requiring clinical assessment and ongoing monitoring.

There may be something South Africa can learn from this approach.

So, what is the legal pathway to medical cannabis in South Africa?

Can Doctors Prescribe Medical Cannabis in South Africa?

South Africa already has a regulatory pathway through which authorised healthcare practitioners can apply for access to certain cannabis-based medicines for their patients.

However, that system is currently facing serious challenges.

The South African Health Products Regulatory Authority (SAHPRA) regulates medicines, including cannabis-based medicinal products.

Under Section 21 of the Medicines and Related Substances Act, authorised healthcare practitioners can apply for permission to use unregistered medicines when clinically justified.

For patients requiring certain cannabis-based treatments, this has provided an important route to legally authorised medication.

However, recent reporting suggests that patients and healthcare professionals are experiencing serious difficulties accessing this pathway.

SAHPRA's Section 21 Crisis Leaves Patients in Limbo

While Boots is introducing new medical cannabis services in the UK, South African patients seeking legal access to these medicines are facing a very different situation.

According to a September 2026 investigation by Cannabiz Africa, SAHPRA appeared to have stopped approving new and renewed Section 21 applications for medical cannabis around 18 July 2026.

The publication reported that patients, doctors and medical cannabis suppliers had been left without clear answers about why approvals had stopped or whether another legal pathway would become available.

“That’s over 30 patients in our care alone left without a route to treatment, through no fault of their own.”

Anton Ofield-Kerr, CEO of AKOS BIO Pharmacy, as quoted by Cannabiz Africa.

The affected patients reportedly included people with difficult-to-treat neurological conditions who had been receiving prescribed cannabinoid medicines under medical supervision.

For patients relying on prescribed medicines, losing access to treatment can have serious consequences.

In an October 2026 follow-up report, Cannabiz Africa highlighted growing concern among healthcare providers about the reported interruption to approvals.

The publication also reported that SAHPRA had not provided an official explanation despite repeated requests for comment.

Without that clarification, it’s difficult to determine whether the situation represents a formal policy change, an administrative suspension or another regulatory problem.

However, the accounts of affected patients and providers suggest that access to legally prescribed treatment has become increasingly uncertain.

A Growing Call for Government Intervention

The controversy has prompted a broader response from South Africa’s cannabis community, with advocacy organisation Fields of Green for ALL playing a leading role in calls for government intervention.

In an 11 November 2026 report, Cannabiz Africa revealed that the Cannabis Crisis Coalition (CCC) had received more than 1,000 endorsements for an open letter calling on President Cyril Ramaphosa to address the country’s ongoing cannabis regulatory uncertainty.

Fields of Green for ALL helped coordinate support for the appeal, bringing together patients, healthcare professionals, cultivators, businesses and cannabis rights advocates.

Myrtle Clarke, CEO of Fields of Green for ALL, highlighted the willingness of supporters to publicly back the campaign.

“What’s interesting is that over 900 signees were happy to be publicly identified”

Among the coalition’s demands is the urgent restoration of effective Section 21 access for patients with serious, treatment-resistant conditions.

The coalition has also called for clearer regulations governing quality-assured cannabinoid medicines, alongside broader reforms addressing commercial cannabis activity and constitutional rights.

In a statement published by Fields of Green for ALL, the organisation expressed frustration over the continuing uncertainty and called for a coordinated government response.

It’s an important development because the issue extends beyond the commercial cannabis industry.

Facebook
X
LinkedIn